Wall Street analyst estimates for iBio, Inc. (IBIO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.75 |
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | -3.95 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $394000 | $444000 | $2.0M | $1.6M | $2.4M | $1.9M | 0 | $225000 | $400000 | $100000 |
| Cost of Revenue | 0 | 0 | 0 | $703000 | $1.5M | $3.8M | 0 | 0 | 0 | 0 |
| Gross Profit | $394000 | $444000 | $2.0M | $935000 | $909000 | -$1.9M | 0 | $225000 | $400000 | $100000 |
| Research & Development | $4.1M | $4.0M | $5.5M | $3.6M | $10.0M | $9.8M | $10.3M | $5.2M | $8.3M | $19.6M |
| Selling, General & Admin | $10.6M | $10.7M | $12.3M | $11.4M | $21.9M | $18.0M | $18.5M | $11.7M | $10.7M | $10.6M |
| Operating Expenses | $14.7M | $14.7M | $17.8M | $14.9M | $32.0M | $27.8M | $29.3M | $16.9M | $19.0M | $35.2M |
| Operating Income | -$14.3M | -$14.2M | -$15.8M | -$14.0M | -$31.1M | -$29.7M | -$29.3M | -$16.6M | -$18.6M | -$35.1M |
| EBITDA | -$12.5M | -$12.5M | -$13.9M | -$11.7M | -$28.6M | -$25.7M | -$27.8M | -$14.0M | -$17.0M | -$32.3M |
| Interest Expense | $1.9M | $1.9M | $1.9M | $2.5M | $2.5M | $1.4M | $83000 | $172000 | $212000 | $53000 |
| Pre-tax Income | -$14.5M | -$16.1M | -$17.6M | -$16.4M | -$23.2M | -$29.5M | -$29.3M | -$15.4M | -$18.4M | -$33.0M |
| Income Tax | $347000 | $34000 | -$4000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.5M | -$16.1M | -$17.6M | -$16.4M | -$23.2M | -$50.4M | -$65.0M | -$24.9M | -$18.4M | -$33.0M |
| EPS | $-800.00 | $-770.00 | $-471.65 | $-304.64 | $-59.98 | $-2889.06 | $-106.18 | $-6.50 | $-1.75 | $-0.32 |
| EPS (Diluted) | $-800.00 | $-770.00 | $-471.65 | $-304.64 | $-59.98 | $-2889.06 | $-106.18 | $-6.50 | $-1.75 | $-0.32 |
| Shares Outstanding (Diluted) | $17822 | $21262 | $37852 | $125590 | $391240 | $17442 | $612250 | $3.8M | $10.5M | $104.1M |
Price
| Price | $1.18 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANTX · BOLD · CVKD · INTS · ITRM · KLTO · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IBIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks